Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Survival Improvement for Acute Myeloid Leukemia Patients Treated in Routine Practice By Intensive Chemotherapy Between 2000 and 2014

Sarah Bertoli, MD PhD, Emilie Bérard, MD PhD, Suzanne Tavitian, MD, Anne Huynh, MD, Cecile Borel, MD, Sarah Guenounou, Isabelle Luquet, MD, Eric Delabesse, PharmD, PhD, Audrey Sarry, Guy Laurent, MD PhD, Michel Attal, Françoise Huguet, MD, Christian Récher, MD PhD

Blood (2016) 128 (22): 3996.

https://doi.org/10.1182/blood.V128.22.3996.3996

Published: 2016

Journal Articles

Thrombosis in Immune Thrombocytopenia Patients with Antiphospholipid Antibodies: A Meta-Analysis

Guillaume Moulis, MD, Alexandra Audermard-Verger, MD, Laurent Arnaud, MD PhD, Cécile Luxembourger, MD, François Montastruc, MD, Amelia Maria Gaman, MD, Elisabet Svenungsson, MD, Marco Ruggeri, MD, Matthieu Mahévas, MD PhD, Mathieu Gerfaud-Valentin, MD, Andres Brainsky, MD, Marc Michel, MD, Bertrand Godeau, MD PhD, Guy Laurent, MD PhD, Maryse Mapeyre-mestre, MD PhD, Laurent Sailler, MD PhD

Blood (2015) 126 (23): 1051.

https://doi.org/10.1182/blood.V126.23.1051.1051

Published: 2015

Journal Articles

Multicellular Aggregates Of Lymphoma Cells (MALC): An Invaluable Model For Studying Follicular Lymphoma Biology and Mechanisms Of Action Of Therapeutic Drugs Such As Anti-CD20 Antibodies

Christine Bezombes, PhD, Emilie Decaup, PhD, Pauline Gravelle, PhD, Christine Jean, PhD, Camille Laurent, MD, Christian Klein, PhD, Nathalie Varoqueaux, MD PHD, Ariel Savina, PhD, Jean-Jacques Fournié, PhD, Guy Laurent, MD PHD

Blood (2013) 122 (21): 4410.

https://doi.org/10.1182/blood.V122.21.4410.4410

Published: 2013

Journal Articles

Relative Impact of NOTCH1/SF3B1 Mutations, Complex Karyotype and TP53 Disruption in the Prognosis of Chronic Lymphocytic Leukemia Patients.

Loic Ysebaert, MD PhD, Stephanie Struski, Nais Prade, Romain Guieze, MD, Guy Laurent, MD PHD, Eric Delabesse, MD, PhD

Blood (2012) 120 (21): 2879.

https://doi.org/10.1182/blood.V120.21.2879.2879

Published: 2012

Journal Articles

Obinutuzumab (GA101) Displays Higher Efficiency Than Rituximab in a Follicular Lymphoma 3D Model

Emilie Decaup, Christine Jean, PhD, Camille Laurent, MD, Pauline Gravelle, Séverine Fruchon, PhD, Florence Capilla, Alain Marrot, Talal AlSaati, MD, François-Xavier Frenois, Guy Laurent, MD PHD, Christian Klein, PhD, Jean-Jacques Fournié, PhD, Nathalie Varoqueaux, MD PHD, Christine Bezombes, PhD

Blood (2012) 120 (21): 4868.

https://doi.org/10.1182/blood.V120.21.4868.4868

Published: 2012

Journal Articles

Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and At the End of Treatment with R-CHOP in High-Tumor Mass Follicular Lymphoma Patients: A GELA-GOELAMS Study

Jehan Dupuis, MD, Michel Meignan, MD, Anne Julian, MD, Christelle Tychyj-Pinel, MD, Alina Berriolo-Riedinger, MD, Pauline Brice, MD, Herve Tilly, Nicolas Mounier, MD, PhD, Andrea Gallamini, MD, Nathalie Berenger, MD, Guy Laurent, MD PHD, Corinne Haioun, Gilles Andre Salles, MD, PhD

Blood (2011) 118 (21): 877.

https://doi.org/10.1182/blood.V118.21.877.877

Published: 2011

Journal Articles

Involvement of the Syk-mTOR Pathway in Follicular Lymphoma Cell Invasion and Angiogenesis,

Christine Bezombes, Séverine Fruchon, Samar Kheirallah, Talal AlSaati, Loic Ysebaert, MD PhD, Camille Laurent, MD, Jean-Jacques Fournié, PhD, Guy Laurent, MD PHD

Blood (2011) 118 (21): 3656.

https://doi.org/10.1182/blood.V118.21.3656.3656

Published: 2011

Journal Articles

The Cell Cycle Regulator CDC25A Is a Target for JAK2 V617F Oncogene

Emilie-Fleur Gautier, Christian Recher, MD, PHD, Camille Laurent, MD, Caroline Marty, PhD, Jean-Luc Villeval, PhD, Cécile Demur, MD, Francois Delhommeau, PharmD, PhD, Elizabeth Hexner, MD, Stephane Giraudier, MD, PhD, Nicolas Bonnevialle, MD, Bernard Ducommun, MD, PhD, Guy Laurent, MD PHD, Stéphane Manenti, PhD, Véronique Mansat- De Mas, PharmD, PhD

Blood (2011) 118 (21): 1385.

https://doi.org/10.1182/blood.V118.21.1385.1385

Published: 2011

Journal Articles

Home Azacitidine Administration in High Risk Myelodysplastic Syndromes: Favorable Results of a Pilot Study in 48 Patients

Sylvestre Guillevic, Thibault Comont, Jonathan Khalifa, Christian Recher, MD, PHD, Daniel Adoue, Sylvie Ollier, Pierre Cougoul, Guy Laurent, MD PHD, Odile Beyne-Rauzy, MD, PhD

Blood (2011) 118 (21): 1719.

https://doi.org/10.1182/blood.V118.21.1719.1719

Published: 2011

Journal Articles

“Don't Eat me”: CD47 and LFA-1 Modulate CLL Response to Nurselike Cells-Mediated Antibody-Dependent Phagocytosis Induced by Rituximab and Obinutuzumab (GA101)

Loic Ysebaert, MD PhD, Emilie Laprevotte, Christian Klein, PhD, Guy Laurent, MD PHD, Anne Quillet-Mary, Mary Poupot, Jean-Jacques Fournié, PhD

Blood (2011) 118 (21): 1762.

https://doi.org/10.1182/blood.V118.21.1762.1762

Published: 2011

Journal Articles

PET Evaluation Before Autografting Has a Strong Prognostic Impact in High-Risk, Relapsed Follicular Lymphoma Patients

Loic Ysebaert, MD PhD, Jehan Dupuis, MD, Michel Meignan, MD, Anne Julian, MD, Christian Recher, MD, PhD, Murielle Roussel, Lucie Oberic, MD, Karim Belhadj, MD, Francoise Rigal-Huguet, MD, Anne Huynh, MD, Camille Laurent, MD, Philippe Gaulard, MD, Michel Attal, MD, Corinne Haioun, MD, Guy Laurent, MD PHD

Blood (2011) 118 (21): 1612.

https://doi.org/10.1182/blood.V118.21.1612.1612

Published: 2011

Journal Articles

Granulocyte-Colony Stimulating Factor Use in Young Fit CLL Patients Receiving Fludarabine-Cyclophosphamide-Rituximab Frontline: Impact on Outcomes, Relative Dose Intensity and Toxicities

Emmanuelle Bouvet, Lucie Oberic, MD, Christian Recher, MD, PHD, Françoise Huguet, MD, Xavier Carles, MD, Guy Laurent, MD PHD, Loic Ysebaert, MD PhD

Blood (2011) 118 (21): 1798.

https://doi.org/10.1182/blood.V118.21.1798.1798

Published: 2011

Journal Articles

High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial

Blood (2010) 116 (21): 1758.

https://doi.org/10.1182/blood.V116.21.1758.1758

Published: 2010

Journal Articles

A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B

Blood (2010) 116 (21): 109.

https://doi.org/10.1182/blood.V116.21.109.109

Published: 2010

Journal Articles

Chronic Lymphocytic Leukemia-Associated Macrophages: Not Just Nurse Cells

Loic Ysebaert, Mary Poupot, Yovan Sanchez-Ruiz, Camille Laurent, Guy Laurent, MD, Jean-Jacques Fournié, PhD

Blood (2010) 116 (21): 46.

https://doi.org/10.1182/blood.V116.21.46.46

Published: 2010

Journal Articles

Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells

Loic Ysebaert, Emilie Laprévotte, Christian Klein, PhD, Guy Laurent, MD, Jean-Jacques Fournié, PhD, Anne Quillet-Mary

Blood (2010) 116 (21): 2459.

https://doi.org/10.1182/blood.V116.21.2459.2459

Published: 2010

Journal Articles

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Guy Laurent, MD, PhD, Sylvie Lafaye de Micheaux, MD, Philippe Solal-Celigny, MD, Pierre Soubeyran, MD, PhD, Vincent Delwail, Hervé Ghesquières, MD, Catherine Thieblemont, MD, Eric Jourdan, MD, PhD, Lucile Beautier, Fabien Audibert, Patrick Squiban, MD, Helene Sicard, PhD, Jean-Francois Rossi, MD, PhD

Blood (2009) 114 (22): 1649.

https://doi.org/10.1182/blood.V114.22.1649.1649

Published: 2009

Journal Articles

Enzastaurin Displays Activity against Follicular Lymphoma Cells: Role of mTOR Pathway

Samar Kheirallah, Loic Ysebaert, Ludivine Leseux, Karim Benhadji, Guy Laurent, MD, Christine Bezombes

Blood (2008) 112 (11): 2609.

https://doi.org/10.1182/blood.V112.11.2609.2609

Published: 2008

Journal Articles

A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vã9Vä2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data.

Guy Laurent, MD, PhD, Jean François Rossi, MD, PhD, Eric W Van Den Neste, MD, PhD, Fabien Audibert, Hervé Ghesquières, MD, Steven Le Gouill, MD, PhD, Pierre Feugier, MD, Helene Sicard, PhD, Sophie Ingoure, Elodie Soule, Sylvie Lafaye de Micheaux, MD

Blood (2008) 112 (11): 1002.

https://doi.org/10.1182/blood.V112.11.1002.1002

Published: 2008

Journal Articles

ALK Activates a Non-Canonical Beta-catenin Pathway in Anaplastic Large Cell Lymphoma

Loic Ysebaert, Laurence Lamant, Estelle Espinos, Sylvie Giuriato, Georges Delsol, Guy Laurent, MD

Blood (2008) 112 (11): 5265.

https://doi.org/10.1182/blood.V112.11.5265.5265

Published: 2008

NARROW

Survival Improvement for Acute Myeloid Leukemia Patients Treated in Routine Practice By Intensive Chemotherapy Between 2000 and 2014

Thrombosis in Immune Thrombocytopenia Patients with Antiphospholipid Antibodies: A Meta-Analysis

Multicellular Aggregates Of Lymphoma Cells (MALC): An Invaluable Model For Studying Follicular Lymphoma Biology and Mechanisms Of Action Of Therapeutic Drugs Such As Anti-CD20 Antibodies

Relative Impact of NOTCH1/SF3B1 Mutations, Complex Karyotype and TP53 Disruption in the Prognosis of Chronic Lymphocytic Leukemia Patients.

Obinutuzumab (GA101) Displays Higher Efficiency Than Rituximab in a Follicular Lymphoma 3D Model

Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and At the End of Treatment with R-CHOP in High-Tumor Mass Follicular Lymphoma Patients: A GELA-GOELAMS Study

Involvement of the Syk-mTOR Pathway in Follicular Lymphoma Cell Invasion and Angiogenesis,

The Cell Cycle Regulator CDC25A Is a Target for JAK2 V617F Oncogene

Home Azacitidine Administration in High Risk Myelodysplastic Syndromes: Favorable Results of a Pilot Study in 48 Patients

“Don't Eat me”: CD47 and LFA-1 Modulate CLL Response to Nurselike Cells-Mediated Antibody-Dependent Phagocytosis Induced by Rituximab and Obinutuzumab (GA101)

PET Evaluation Before Autografting Has a Strong Prognostic Impact in High-Risk, Relapsed Follicular Lymphoma Patients

Granulocyte-Colony Stimulating Factor Use in Young Fit CLL Patients Receiving Fludarabine-Cyclophosphamide-Rituximab Frontline: Impact on Outcomes, Relative Dose Intensity and Toxicities

High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial

A Prospective Randomized Study Comparing Dose Intensive Immunochemotherapy with R-ACVBP vs Standard R-CHOP In Younger Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Study LNH03-2B

Chronic Lymphocytic Leukemia-Associated Macrophages: Not Just Nurse Cells

Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Enzastaurin Displays Activity against Follicular Lymphoma Cells: Role of mTOR Pathway

A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vã9Vä2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data.

ALK Activates a Non-Canonical Beta-catenin Pathway in Anaplastic Large Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only